As an antiandrogen drug, bicalutamide can bind to the androgen receptor in the body with high intensity, thus reducing the growth-promoting effect of testosterone and dihydrotestosterone on cancer cells, maximally controlling the metastasis of prostate cancer cells and consolidating the therapeutic effect. This evidence concerns the gene AR and Familial prostate cancer.